neomycin sulfate, polymyxin b sulfate and hydrocortisone

FDA Drug Profile — Neomycin and Polymyxin B Sulfates and Hydrocortisone, NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

neomycin sulfate, polymyxin b sulfate and hydrocortisone is listed in the FDA National Drug Code directory with 11 NDC codes, marketed under brand names including Neomycin and Polymyxin B Sulfates and Hydrocortisone, NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE. Available dosage forms: suspension, suspension/ drops, solution.

Drug details

Generic Name
neomycin sulfate, polymyxin b sulfate and hydrocortisone
Brand Names
Neomycin and Polymyxin B Sulfates and Hydrocortisone, NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Application Number
ANDA062488
Sponsor
Preferred Pharmaceuticals Inc.
NDC Codes
11
Dosage Forms
SUSPENSION, SUSPENSION/ DROPS, SOLUTION
Routes
AURICULAR (OTIC), OPHTHALMIC
Active Ingredients
NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE

Indications and Usage

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

Warnings

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days [see Error! Hyperlink reference not valid. ] . Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation occurs. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.